113 related articles for article (PubMed ID: 14770080)
1. Augmentation of antitumor immune responses by multiple intratumoral inoculations of replication-conditional HSV and interleukin-12.
Iizuka Y; Suzuki A; Kawakami Y; Toda M
J Immunother; 2004; 27(2):92-8. PubMed ID: 14770080
[TBL] [Abstract][Full Text] [Related]
2. Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV.
Toda M; Iizuka Y; Kawase T; Uyemura K; Kawakami Y
Cancer Gene Ther; 2002 Apr; 9(4):356-64. PubMed ID: 11960286
[TBL] [Abstract][Full Text] [Related]
3. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity.
Toda M; Rabkin SD; Kojima H; Martuza RL
Hum Gene Ther; 1999 Feb; 10(3):385-93. PubMed ID: 10048391
[TBL] [Abstract][Full Text] [Related]
4. In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer.
Endo T; Toda M; Watanabe M; Iizuka Y; Kubota T; Kitajima M; Kawakami Y
Cancer Gene Ther; 2002 Feb; 9(2):142-8. PubMed ID: 11857031
[TBL] [Abstract][Full Text] [Related]
5. In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity.
Toda M; Martuza RL; Kojima H; Rabkin SD
J Immunol; 1998 May; 160(9):4457-64. PubMed ID: 9574551
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters.
Nakano K; Todo T; Chijiiwa K; Tanaka M
Mol Ther; 2001 Apr; 3(4):431-7. PubMed ID: 11319903
[TBL] [Abstract][Full Text] [Related]
7. Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.
Chahlavi A; Todo T; Martuza RL; Rabkin SD
Neoplasia; 1999 Jun; 1(2):162-9. PubMed ID: 10933051
[TBL] [Abstract][Full Text] [Related]
8. Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy.
Todo T; Rabkin SD; Chahlavi A; Martuza RL
Hum Gene Ther; 1999 Nov; 10(17):2869-78. PubMed ID: 10584932
[TBL] [Abstract][Full Text] [Related]
9. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
Todo T; Martuza RL; Dallman MJ; Rabkin SD
Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
[TBL] [Abstract][Full Text] [Related]
10. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus.
Todo T; Rabkin SD; Sundaresan P; Wu A; Meehan KR; Herscowitz HB; Martuza RL
Hum Gene Ther; 1999 Nov; 10(17):2741-55. PubMed ID: 10584921
[TBL] [Abstract][Full Text] [Related]
11. Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models.
Nakano K; Todo T; Zhao G; Yamaguchi K; Kuroki S; Cohen JB; Glorioso JC; Tanaka M
J Gene Med; 2005 May; 7(5):638-48. PubMed ID: 15754306
[TBL] [Abstract][Full Text] [Related]
12. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM.
Markert JM; Liechty PG; Wang W; Gaston S; Braz E; Karrasch M; Nabors LB; Markiewicz M; Lakeman AD; Palmer CA; Parker JN; Whitley RJ; Gillespie GY
Mol Ther; 2009 Jan; 17(1):199-207. PubMed ID: 18957964
[TBL] [Abstract][Full Text] [Related]
13. Intravesical and intravenous therapy of human bladder cancer by the herpes vector G207.
Oyama M; Ohigashi T; Hoshi M; Nakashima J; Tachibana M; Murai M; Uyemura K; Yazaki T
Hum Gene Ther; 2000 Aug; 11(12):1683-93. PubMed ID: 10954902
[TBL] [Abstract][Full Text] [Related]
14. Combination suicide/cytokine gene therapy as adjuvants to a defective herpes simplex virus-based cancer vaccine.
Toda M; Martuza RL; Rabkin SD
Gene Ther; 2001 Feb; 8(4):332-9. PubMed ID: 11313808
[TBL] [Abstract][Full Text] [Related]
15. A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes.
Carew JF; Kooby DA; Halterman MW; Kim SH; Federoff HJ; Fong Y
Mol Ther; 2001 Sep; 4(3):250-6. PubMed ID: 11545616
[TBL] [Abstract][Full Text] [Related]
16. Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice.
Chahlavi A; Rabkin S; Todo T; Sundaresan P; Martuza R
Gene Ther; 1999 Oct; 6(10):1751-8. PubMed ID: 10516725
[TBL] [Abstract][Full Text] [Related]
17. Immuno-viral therapy as a new approach for the treatment of brain tumors.
Toda M
Drug News Perspect; 2003 May; 16(4):223-9. PubMed ID: 12942152
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration.
Hara I; Nagai H; Miyake H; Yamanaka K; Hara S; Micallef MJ; Kurimoto M; Gohji K; Arakawa S; Ichihashi M; Kamidono S
Cancer Gene Ther; 2000 Jan; 7(1):83-90. PubMed ID: 10678360
[TBL] [Abstract][Full Text] [Related]
19. Design and Rationale for First-in-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors.
Bernstock JD; Bag AK; Fiveash J; Kachurak K; Elsayed G; Chagoya G; Gessler F; Valdes PA; Madan-Swain A; Whitley R; Markert JM; Gillespie GY; Johnston JM; Friedman GK
Hum Gene Ther; 2020 Oct; 31(19-20):1132-1139. PubMed ID: 32657154
[TBL] [Abstract][Full Text] [Related]
20. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207.
Walker JR; McGeagh KG; Sundaresan P; Jorgensen TJ; Rabkin SD; Martuza RL
Hum Gene Ther; 1999 Sep; 10(13):2237-43. PubMed ID: 10498254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
